Tables
- TABLE 1
Patient characteristics and response to antibody therapy
All Ex-smokers Nonsmokers p-value Patients 158 48 (30) 110 (70) Females 102 (65) 21 (44) 81 (74) 0.010* Age, years 53.4±14.67 58.88±11.40 51.07±15.33 0.002* BMI, kg·m−2 28.56±6.41 28.90±4.89 28.41±6.99 0.060 Duration of the disease, years 26.47±16.33 24.42±18.65 26.94±15.30 0.045* Smoking pack-years 21.70±18.07 27.98±17.4 4.94±1.83 <0.001* Comorbidities COPD 36 (33) 24 (50) 12 (11) <0.001* Emphysema 19 (12) 10 (21) 9 (8) 0.017* Allergy 92 (84) 27 (56) 66 (60) 0.331 Atopic dermatitis 18 (16) 3 (6) 15 (14) 0.095 Chronic sinusitis/nasal polyps 70 (64) 17 (35) 53 (48) 0.078 Obstructive sleep apnoea 16 (15) 8 (17) 8 (7) 0.287 Gastro-oesophageal reflux 11 (10) 3 (6) 8 (7) 0.891 Obesity# 17 (15) 3 (6) 14 (13) 0.107 ACT score At baseline 12.87±5.45 10.78±4.02 12.11±4.76 0.353 At follow-up 16.50±5.88 16.13±6.03 16.66±5.83 0.568 Δ pre- to post-treatment 4.07±5.71 4.60±6.08 3.83±5.55 0.423 FEV1, L At baseline 1.97±0.80 1.66±0.60 2.10±0.84 0.007* At follow-up 2.11±0.77 1.86±0.68 2.21±0.80 0.263 Δ pre- to post-treatment 0.14±0.42 0.21±0.36 0.12±0.46 0.538 Exacerbation rate At baseline 4.08±4.16 4.90±4.05 3.73±4.17 0.598 At follow-up 0.22±0.63 0.25±0.94 0.21±0.43 0.240 Δ pre- to post-treatment −3.89±4.12 −4.79±4.14 −3.49±4.06 0.518 Regular oral corticosteroid dose, mg·day−1 At baseline 7.15± 8.32 8.33±7.45 6.62±8.67 0.700 At follow-up 2.35±4.76 3.50±5.48 1.84±4.33 0.170 Δ pre- to post-treatment −3.91±8.74 −3.79±10.35 −3.97±7.97 0.200 Data are presented as n, n (%) or mean±sd, unless otherwise stated. BMI: body mass index; ACT: Asthma Control Test; FEV1: forced expiratory volume in 1 s. #: BMI >30 kg·m−2. *: significant p-value, p<0.05.
Vol 7 Issue 3
Table of Contents
Impact of prior smoking exposure and COPD comorbidity on treatment response to monoclonal antibodies in patients with severe asthma
